Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists by unknown
Interleukin 5 Modifies Histamine Release and
Leukotriene Generation by Human Basophils in
Response to Diverse Agonists
By Stephan C. Bischoff, Thomas Brunner,
Alain L. De Weck, and Clemens A. Dahinden
From the Institute of Clinical Immunology, Inselspital, CH-3010 Bern, Switzerland
Summary
Human interleukin 5 (IL5), known as a selective colony-stimulating factor of the eosinophil
lineage and activator of mature eosinophils, also profoundlyinfluences the mediator release profile
of human basophils. IL5 by itself triggers neither granule release nor de novo synthesis of lipid
mediators. However, at low concentrations (0.1-10 ng/ml), IL5 rapidly primes basophils for
enhanced histamine release and leukotriene C4 (LTC4) generation in response to all established
basophil agonists. LTC4 generation is more strongly affected by 11,5 than histamine release. In
particular, IL5 renders basophils capable of producing large quantities of LTC4 in response to
C5a, which, without the cytokine, induces histamine release only. Finally, IL5 renders basophils
responsive to agonists (neutrophil-activating peptide 1 and C3a), which are otherwise inefficient
triggers for basophil mediator release. The effects are similar to the recently established bioactivity
of IIL3 on basophils, with the exception of its influence on IgE-dependent basophil activation,
which is less pronounced. Thus, IL5 strongly modulates the function not only of eosinophils
but also of basophils, the two major effector leukocyte types involved in allergic inflammatory
processes, e.g., in asthma.
n contrast to most cytokines, which have a pleiotropic ac-
tion on a variety of cell types, the biological activity of
human IL5 has been assumed to be restricted to the eosino-
phil cell lineage (1-3). IL5 stimulates the growth and differen-
tiation ofhuman eosinophil progenitors without influencing
cells committed to neutrophils, basophils, or monocytes (1).
Moreover, IL5 selectively enhances the responsiveness of ma-
ture eosinophils, inducing polarization, shape change, and
chemotaxis, enhancing cytotoxicity and oxygen radical re-
lease, as well as prolonging their survival, particularly in the
presence of fibroblasts (2, 3). However, effects on other ma-
ture inflammatory effector cells have not yet been described.
Murine IL5 (T cell replacing factor, B cell growth factor II)
has been originally isolated and cloned according to its ac-
tivity on B cells (4). The human IL5 has never been purified
to homogeneity from stimulated leukocytes, but was recently
cloned using the murine IL5 cDNA as a hybridization probe
(5) . In contrast to the mouse system, however, IL5 seems
to be inactive on human B cells (6).
Beside eosinophils, human basophils presumably play an
important role in the late phase of allergic reactions, as well
as in certain types of delayed-type hypersensitivity (7, 8). The
extent of mediator release by basophils may therefore be of
particular relevance to the severity of symptoms in allergic
diseases (8). Recent studies showed that the multipotent he-
matopoietic growth factor IL3 enhances the release of inflam-
matory mediators not only from eosinophils (9) but also from
basophils (10-12). Furthermore, granulocyte/macrophage CSF
(GM-CSF)l enhances the responsiveness of all mature my-
eloidcells including basophils (13, 14, and unpublished results).
Here, we demonstrate that the biological activity of IL5 is
not restricted to eosinophils, since this cytokine profoundly
modifies the basophil response to diverse cell agonists. In par-
ticular, IL5 most strongly affects de novo synthesis of leu-
kotriene C4 (LTC4), further supporting the concept ofa major
regulatory role ofhematopoietic growth factors in lipidmedi-
ator generation by inflammatory effector cells (9-14). Our
results also show that IL5 together with IL3 and GM-CSF
belongs to a particular set of cytokines, able to modify the
function of eosinophils as well as basophils, the two predom-
inant effector cell types infiltrating allergic inflammatory sites.
Materials and Methods
Reagents.
￿
Dextran, Ficoll Hypaque, and Percoll were obtained
from Pharmacia Fine Chemicals (Uppsala, Sweden); Hepes was from
Calbiochem-Behring Corp. (La Jolla, CA); BSA, fatty acid free,
1 Abbreviations used in thispaper . GM-CSF, granuloryte/macrophage CSF;
LTC4, leukotriene C4; NAP-1, neutrophil-activating peptide 1.
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was from Fluka AG (Buchs, Switzerland); and Dynabeads M-450
Pan T was from Dynal A.S. (Skoyen, Norway).
Cell Preparation.
￿
Basophils were prepared from venous blood
of unselectedhuman volunteersexactly as describedin detailprevi-
ously (10). For most experiments, PBMC depleted of neutrophils
and eosinophils by Ficoll-Hypaque density centrifugations con-
taining 1-8% (mean, 3%) basophils were used (10). In some ex-
periments, whole leukocytes were fractionated by Percoll density
centrifugation as described (10), resulting indifferent fractions con-
taining variable proportions ofleukocyte types, including one frac-
tion consisting of 15-40% basophils and contaminated exclusively
with smalllymphocytes. In two experiments, the basophil-enriched
Percoll fraction was depleted of T lymphocytes using immunomag-
neticbeads coated with mouse anti-CD2 mAb. This procedure in-
creased basophil purity from 32 and 38% to 88 and 94%, respec-
tively, decreasing the lymphocyte contamination to 12 and 6%.
Cell Stimuli.
￿
Human rII,5, expressed in Escherichia coli and
purified to at least 95%, as assessed by SDS-PAGE, was obtained
from Amgen Biologicals (Thousand Oaks, CA). Its biological ac-
tivity (106 U/mg) has been determined in a bone marrow progen-
itor cell assay ofcell proliferation and differentiationinto eosinophils.
Human rII,3 (bioactivity, 0.7 x 106 U/mg in a proliferation assay
with cultures of leukocytes from patients with chronic myeloic
leukemia), human rGM-CSF (bioactivity, 3.7 x 106 U/mg in the
same assay as for IL3), and human recombinant neutrophil-
activatingpeptide 1(rNAP-1) (11) were from Sandoz (Basel, Swit-
zerland and Vienna, Austria, respectively). r11L113 (bioactivity, 107
U/mg, determined in a LAF inhibition assay) was obtained from
Biogen-Glaxo S.A. (Gene`ve, Switzerland). The complementcleavage
products C3a and C5a were purified from yeast-activated human
serumas described (10, 12). FMLP (Bachem AG, Bubendorf, Swit-
zerland) and mouse anti-IgE mAb LE27 (12) were dissolved in PBS.
All agents were stored in small aliquots at - 70°C and thawedjust
before use.
Mediator ReleaseAssay.
￿
Cellswere suspended in HACM buffer
(20 mM hepes, 125 rnM NaCl, 5 mM KCI, 0.5 mM glucose,
0.025% BSA, 1 MM CaC12, I mM MgC12) at a cell density of
3-5 x 106 cells/ml, except for pure basophils (0.2-0.5 x 106
cells/ml). The release experiments were performed in a shaking
water bath at 37°C. After a warming-up period of 10 min, the
cells were preincubated with cytokines (IL5, IL3, IL-10, GM-CSF)
or in buffer for 10 min, followedby addition ofthe triggeringagent
(C5a, anti-IgE, FMLP, NAP-1, C3a). The reaction was stopped
20 min after addition of the second stimulus, a time determined
to be sufficient for a complete mediator release reaction for all the
agonists studied. Histamine and LTC4 release were measured as
described (10-12).
Data Presentation.
￿
Histamine release is expressed as percent of
total histamine content per tube aftercell lysis. Leukotriene data
are presented as picograms LTC4 per nanograms total cellular hista-
mine content in order to correct for different basophil numbers;
except for experiments with highly purified basophils, where leu-
kotriene data are expressed as nanograms LTC4 per 106 basophils.
Results
11,5 Modifies Basophil Mediator Release Triggered by IgE-
dependent and IgE-independent Agonists. Table 1 shows that
histamine release from basophils triggered with maximally
effective concentrations of C5a, anti-IgE, or FMLP is con-
siderably augmented when cells have been preincubated for
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Table 1.
￿
Effect ofIL-5 Preincubation upon Basophil Histamine
Release Induced by Various Agonists and Comparison with
other Cytokines
Cells were preincubated in buffer (O) or with cytokines (IL-5, IL-3,GM-
CSF: 10 ng/ml; IL-1/3: 100 ng/ml) for 10 min and further incubated
in buffer (O), or stimulatedfor 20 min by C5a (10-s M), anti-IgE (aIgE;
100 t~g/ml), FMLP (2.5 x 10-6 M), C3a (10-6 M), or NAP-1 (10- 7
M) as second signals. The mean of histamine release from threeseparate
experiments, each performed in triplicate, with cells from a representa-
tive donor is shown. The SD of triplicates was <5% of the mean, and
that of the three experiments was <15% of the mean.
10 min with 10 ng/ml human rlIT5. De novo synthesis of
lipidmediators is even more strongly enhanced (Table 2). In
particular, IIL5-primed basophils produce large quantities of
LTC4 in response to C5a, which by itself is unable to pro-
mote lipid mediator synthesis (10). For comparison, the effects
of the three other cytokines known to affect basophil medi-
ator release (10-12, 14) have been examined within the same
experiments. These results show that IL5, 1163, and GM-
CSF modulate basophil mediator release in response to all
agonists in a qualitatively identical manner. IL5, by itself,
neither induces histamine release above that of the buffer con-
trol nor causes LTC4 generation above the detection limit
(Tables 1 and 2 and see Figure 2).
In some experiments, the different hematopoietic growth
factors have been added simultaneously in various combina-
tions, all at maximally effective concentrations of 10 ng/ml
(IL3 + GM-CSF, IL3 + IL5, IL5 + GM-CSF, IL3 +
IL5 + GM-CSF), 10 min before stimulating the basophils
with C5a. No further increase of histamine release and leu-
kotriene generation over that observed in cells primed by the
different cytokines alone can be measured (data not shown) .
By contrast, the effects of ILlO, which has been reported
to enhance IgE-mediated histamine release (15), are only mar-
ginal, even at the maximally effective concentration of 100
ng/ml. Additionally, I1L1S is unable to render basophils capable
of producing LTC4 in response to C5a (Table 2).
IL5 Renders Basophils Responsive to NAP-1 and C3a.
￿
In
previous studies, we have shown that, in contrast to other
chemotactic factors such as C5a and FMLP, the cell-derived
NAP-1, by itself, neither induces histamine release nor LTC4
generation, at least at physiologically relevant concentrations
Histamine release
O
(percent
C5a
of total
aIgE
histamine
FMLP
content)
C3a NAP-1
0 5 .1 43.4 35.6 39.8 5.3 5 .1
IL-5 5 .8 74.5 57.1 62 .0 15.9 17.3
IL-3 8.6 76.3 73.0 61.3 16.9 17.4
GM-CSF 5.7 71.8 70.1 58.3 16.1 18 .8
IL-1/3 5 .4 43.7 36.2 38.9 6.6 8 .1Table 2.
￿
Effect of IL-5 Preincubation upon Leukotriene C4
Generation by Basophils in Response to Various Agonists and
Comparison with other Cytokines
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Cells were preincubated in buffer (O) or with cytokines (IL-5, IL-3, GM-
CSF: 10 ng/ml; IL-1,8: 100 ng/ml) for 10 min and further incubated
in buffer (O), or stimulated for 20 min by C5a (10-s M), anti-IgE (aIgE;
100 Ag/ml), FMLP (2.5 x 10-6 M), C3a (10-6 M), or NAP-1 (10-7
M) as second signals. The mean of leukotriene generation from three
separate experiments, each performed in triplicate, with cells from a
representative donor is shown. The SD of triplicates was <5% of the
mean, and that of the three experiments was <15% of the mean.
Of up to 10 -7 M. In IIr3-primed basophils, however, NAP-1
becomes an efficient trigger for basophil mediator release (11).
Similarly, the complement component C3a is an inefficient
basophil agonist, even at a concentration of 10 -6 M, but in
the presence of IIr3 or GM-CSF, it triggers basophil medi-
ator release even at a 1,000-fold lower concentration of C3a
(12) . The present study demonstrates that IL5 renders
basophils responsive to NAP-1 as well as to C3a in a manner
identically to IL3 and GM-CSF (Tables 1 and 2).
HighlyPurified Basophils.
￿
To determine the cellular source
of LTC4 and to exclude an indirect action of 116, we purified
basophils up to 94%. The pattern of mediator release and
the modulatory effect of IL5 is found to be independent of
the basophil purity. Using 94% pure basophils at 0.5 x 106
cell/ml, it can be confirmed at a much lower detection limit
that C5a is unable to induce LTC4 synthesis (<0.05 ng
LTC4/106 basophils), but efficiently stimulates histamine re-
lease (65% vs. 2% in controls). In the presence of 116, this
cell preparation produces 15.7 ± 1.2 ng LTC4/106 basophils
in response to C5a (mean ± SD, n = 4). FMLP-induced
LTC4 synthesis is enhanced from 8 .2 ± 0.7 to 21.4 ± 1.5
ng LTC4/106 basophils by IL5 preincubation. Furthermore,
PBMC and PMN (93% neutrophils, 7% eosinophils) depleted
of basophils by Percoll gradients do not produce detectable
amounts of LTC4 in response to the different agonists with
or without 11,5 priming (<0.01 ng LTC4/106 cells).
Variability ofBasophil MediatorRelease
￿
Triggering the cells
of different unselected donors with anti-IgE, C5a, or FMLP
results in considerable differences in releaseability (Fig. 1),
which have been reported repeatedly. In agreement with
previous studies, no correlation was found between the ex-
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Figure 1.
￿
IIr5- and IIr3-induced modulation of basophil mediator re-
lease: comparison ofdifferent donors. Basophils were stimulated with C5a
(10- 8 M; left), anti-IgE (100 ng/ml; middle), or FMLP (2.5 x 10- 6 M;
right) after preincubating the cells during 10 min in buffer or with IL3
or IL5 (10 ng/ml). Histamine release (three upper panels) and leukotriene
generation (three lower panels) from seven experiments performed with
seven different donors are shown. Each point represents the mean of tripli-
cates. The data of each experiment were connected by lines in order to
allow comparison ofmediator release by cells ofdifferent donors. Statistical
analysis (paired t test): IL3 + anti-IgE vs. IL5 + anti-IgE, p < 0.01(hista-
mine) and p < 0.001 (leukotriene); IL-3 + C5a vs. IL5 + C5a or 11,3
+ FMLP vs. 11,5 + FMLP; p > 0.05 (histamine, leukotriene).
tent of mediator release induced by the three different agonists
alone in cells from different donors (regression analysis: C5a
vs. anti-IgE, C5a vs. FMLP, anti-IgE vs. FMLP; all p > 0.05).
In all cases, however, 1175 strongly enhances histamine re-
lease and leukotriene generation, regardless of the different
responsiveness of the cell preparations to a certain agonist.
Even cells from individuals, that do not respond to anti-IgE
alone, so-called "non-responders," release mediators aftercell
priming with IL5 . In addition, all donors generate LTC4
in response to C5a after IL5-preincubation, while LTC4 has
never been detected in supernatants of cells exposed to C5a
alone. An interindividual difference of the total amount of
mediators released, however, is observed with or without
priming with 116. This difference cannot be explained by
day-to-day variability of mediator release, since the SD of ex-
periments performed with different cell preparations of the
same individual repeated up to five times never exceeded 15%
of the mean. In parallel experiments, the effect of IL3 prein-
cubation upon basophil mediator release has been examined
using the cells from the same donors (Fig. 1). IL3 and IL5
modify the basophil response towards IgE-independent
agonists in an identical manner, whereas IL5 is slightly but
reproducibly less efficient in enhancing anti-IgE-induced medi-
ator release (paired t test, p < 0.001). Also worth mentioning,
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Figure 2.
￿
IL5 dose response. Basophils were preincubated in buffer or
with 11,5 at the concentrations indicated. After 10 min, C5a (10 -8 M;
"), anti-IgE (100 ng/ml; "), or buffer control (O) was added for 20
min. (A) Histaminerelease; (B) leukotriene generation. The mean oftripli-
cates ofa representative experiment is shown. Parallel dose-response curves
were obtained with cells from three different donors. The enhancement
by IL5 ofFMLP-induced mediator release occurred over the same concen-
tration range as that of C5a (not shown).
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Figure 3.
￿
Kinetic of the 11,5 priming process. Basophils were prein-
cubated with 10 ng/ml of 11,5 for variable times and then stimulated by
C5a (10-8 M). The time interval between 11,5 and C5a addition is indi-
cated in the x-axis. The upper panel shows histamine release, the lower
panel shows LTC4 generation. Each point represents a single determina-
tion. Data from a typical experiment are shown.
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there are no interindividual differences in the extent ofpriming
by these two cytokines.
DoseResponse ofIL5.
￿
11,5 enhances histamine release and
primes for leukotriene synthesis over a similar concentration
range, regardless of which trigger is used as a second signal.
The effect increases dose dependently from 0.1-3 ng/ml 11,
5, and becomes maximal at 3-10 ng/ml (Fig. 2). The modu-
lation ofthe IgE-dependent basophil response tends to reach
a maximal effect at slightly lowerconcentrations (1-3 ng/ml) .
These data exclude that the somewhat weaker effect of IL5,
as compared with IL3, upon the IgE-dependent basophil re-
sponse (Fig. 1) is due to a suboptimal IIT5 concentration.
Kinetic ofIL5 Priming.
￿
When IL5 is added simultane-
ously with the agonist, no enhancement ofmediator release
is observed (data not shown). Experiments, in which the time
interval between IL5 and C5a addition has been varied, show
that the enhancement ofhistamine release occurs almost im-
mediately after IL5 addition and becomes maximal after 5
min. Priming for C5a-induced LTC4 formation starts after
a lag period of3-4 min, with optimal effects after 9-10 min.
This altered responsiveness remains unchanged up to an ob-
servation period of 40 min (Fig. 3).
Discussion
The present study demonstrates that the biological activity
of human IL-5 is not restricted to cells of the eosinophil lin-
eage but strongly enhances mediator release by mature human
basophils. The data support our concept that a major func-
tion ofhematopoietic growth factors is their ability to allow
the synthesis of lipid mediators by inflammatory effector cells
in response to agonists that are otherwise inactive in this re-
spect (10-13) . The fact that two cellular signals are generally
necessary for lipid mediator synthesis has also been observed
in neutrophils (13), and in monocytes (16). The similarity
of the biological activities between 11,5, IL-3, and GM-CSF
upon basophil function suggests a similarity also in theirmech-
anism of action. This hypothesis is further supported by the
fact that the effect of optimal concentrations of a single growth
factor cannot be enhanced by the combination of these cyto-
kines. In this respect, it is interesting that the receptors of
most leukocyte growth factors, including 110 and GM-CSF,
belong to a large family of structurally related proteins
(erythropoietin receptor family) (see reference 17), and it is
likely that the IL5R also belongs to this class of receptors.
Recent studies have shown that the IL6 ligand-receptor com-
plex, by its extracellular domain, interacts with another mem-
brane protein (GP 130), which seems to mediate signal trans-
duction (18). It is tempting to speculate that IL5, IL3, and
GM-CSF ligand-receptor complexes interact with a similar
protein, which may even be shared amongthese three cytokine
receptors.
There are, however, discrete differences between the priming
effects of 116, GM-CSF, and 110 upon basophil function.
While IL5 and 11,3 modulate the basophil response to all
IgE-independent agonists examined (FMLP, C5a, C3a, NAR
1) in an identical manner, IL5 enhances the anti-IgE-induced
mediator release somewhat less efficiently as compared withIL3. Whereas IL5 alone does not induce any mediator re-
lease, IIr3 occasionally causes a small histamine release above
controls (10). Histamine release induced by IL3 alone is more
readily observed in cell buffers containing D20 (19). 11,5
also induces marginal degranulation when using D20-
containing buffer, but clearly less strongly than that caused
by IL3 (own unpublished results) . The priming process for
enhancement of histamine release and generation of LTC4
in response to C5a proceeds slightly more rapidly by IL3
(10) as compared to IL5 . Finally, the altered stateofbasophil
responsiveness induced by GM-CSF is more transient (un-
published observation) than that induced by 116 or IL3.
The fact that low concentrations of IL5 rapidly, within
minutes, modulate mediator release suggests a direct action
of this rytokine on basophils, presumably through a specific
receptor. The probable lack ofeffects of116 on other human
PBMC (1, 2, 5), and our observation that basophils purified
up to 94% respond identically to IL5 as basophils in PBMC,
further argue against the involvement ofother leukocytes in
the 11,5 effect on basophils. Under the stimulation protocols
used in this study, the basophil is the only relevant source
ofLTC4, since: (a) LTC4 production strongly correlates with
the basophil number and was not affected by the presence
of variable proportions of other leukocyte types in different
cell fractions of Percoll gradients (10, and unpublished results);
and (b) no LTC4 is produced with or without rytokinepriming
by other leukocyte types (e.g., monocytes or neutrophils) de-
pleted of basophils.
IL5 dose dependently modulates basophil mediator release
within a low concentration rangeof 0.1-3 ng/ml. However,
since human 11,5 has been cloned according to its sequence
homology to mouse 11,5 only (5), and since natural IL5 has
not been purified, the potency ofthe human natural product
is yet unknown. Also, the role of glycosylation and homo-
dimer formation has been determined only in the murine
system (20). Therefore, with regard to basophil activation,
the structural requirements for the optimally active form of
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